PremiumThe FlyH.C. Wainwright says competitor data builds optimism for NextCure’s LNCB74 Nextcure Faces Delisting Risk Amid Nasdaq Compliance Struggles NextCure Reports 2024 Financials and Strategic Progress PremiumThe FlyNextCure announces preclinical data on NC605 NextCure Reports Improved Financial Performance and Strategic Focus NextCure to Discuss Innovative Cancer Therapies PremiumThe FlyNextCure reports Q2 EPS (55c), consensus (38c) NextCure presents Phase 1b data on NC410 and pembrolizumab combo at ASCO NextCure treatment of osteogenesis imperfecta granted orphan designation 
